All In Biotech

NDA 210933 · Alcon Labs INC

Eysuvis

Loteprednol Etabonate · Ophthalmic

Novel

Last checked: Nov 19, 2026Latest source record: Oct 26, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Oct 26, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

16 Phase 3, 0 recruiting

FAERS reports

1,098

306 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 11, 2025.

EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. ( 1 )

Mechanism: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and delay or slow healing. Corticosteroids inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. While glucocorticoids are known to bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not clearly established. However, corticosteroids are thought to...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 26, 2020 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLabelLetterReview
1 products under this application
  • EYSUVIS · LOTEPREDNOL ETABONATE 0.25% · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Loteprednol Etabonate" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain232
  • eye irritation153
  • off label use100
  • drug ineffective95
  • ocular hyperaemia75
  • product dose omission issue74
  • headache64
  • vision blurred60
  • photophobia52
  • fatigue51
  • ocular discomfort50
  • eye swelling46

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20053
20081
20092
20104
20112
20123
20135
20143
20158
20165
20176
201812
201920
202031
2021107
2022141
2023159
2024185
2025248
2026150

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Eysuvis (Loteprednol Etabonate)

2024 spending

$12.9M

Beneficiaries

14,882

25,219 claims

Per beneficiary

$867

$58.78 per unit

View as table
YearSpending
2020$0
2021$3,480,006
2022$7,384,602
2023$10,878,526
2024$12,908,618

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Alcon Labs INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.